Reimbursed Care Access in Sao Tome and Principe

Currently classified as a strictly controlled substance under national drug-scheduling obligations derived from São Tomé and Príncipe’s accession to the international drug control conventions (Single Convention on Narcotic Drugs and the Convention on Psychotropic Substances), with no publicly available evidence of authorized medical use or reimbursement outside of approved clinical research. # #

Currently classified as a strictly controlled substance under national drug-scheduling obligations derived from São Tomé and Príncipe’s participation in UN drug control treaties, with no authorized medical use or public reimbursement outside of approved clinical research. # #

There is no public record of a national reimbursement or licensed esketamine (Spravato®) program in São Tomé and Príncipe; given the country’s obligations under the UN drug control conventions and the absence of evidence for local regulatory approvals or reimbursement listings, esketamine is not an authorized, reimbursed psychiatric treatment in routine care and would only be available via regulated import for approved clinical or research purposes if permitted. Note: esketamine is an approved, clinically regulated psychiatric product in some other jurisdictions (e.g., FDA approval in the U.S.), but no national approval/reimbursement information for São Tomé and Príncipe was identified. # #

Ketamine (the racemic anesthetic) is recognized internationally as an essential anesthetic medicine and is widely used in low‑resource and emergency clinical settings; the World Health Organization includes ketamine on the Model List of Essential Medicines, supporting its routine use for anesthesia and analgesia in many health systems worldwide. In São Tomé and Príncipe there is no public evidence of a national reimbursed program for ketamine when used for psychiatric (off‑label) indications; however, ketamine is very likely to be available in the health system for anaesthesia and emergency medicine consistent with WHO guidance, rather than as a reimbursed, structured psychedelic-assisted psychiatric therapy. There is no publicly available national policy or reimbursement schedule showing coverage for ketamine for treatment‑resistant depression or other psychiatric indications in São Tomé and Príncipe. # #

Currently classified as a strictly controlled substance under national drug-scheduling obligations derived from São Tomé and Príncipe’s participation in international drug control treaties, with no authorized medical use or reimbursement outside of approved clinical research. # #

Currently classified as a strictly controlled substance under national drug-scheduling obligations derived from São Tomé and Príncipe’s participation in UN drug control conventions, with no authorized medical use or reimbursement outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug‑scheduling obligations derived from São Tomé and Príncipe’s treaty commitments, with no authorized medical use or reimbursement outside of approved clinical research. There is no public evidence of legal medical or reimbursed ibogaine treatment programs in the country. #

While ayahuasca is a plant‑based preparation composed of DMT-containing admixtures and has cultural/ceremonial use in some countries, under São Tomé and Príncipe’s international drug‑control obligations the principal psychoactive constituents (e.g., DMT) are controlled; there is no public evidence of authorized, reimbursed medical ayahuasca programs in the country and access would be limited to approved clinical research if permitted. #

Currently classified as a strictly controlled substance under São Tomé and Príncipe’s international drug control obligations, with no authorized medical use or reimbursement outside of approved clinical research. No national medical/reimbursement program for mescaline was identified. #

The 2C‑family of phenethylamine psychedelics (2C‑X compounds) are controlled under international psychotropic substance controls and therefore are treated as strictly controlled in São Tomé and Príncipe; there is no authorized medical use or reimbursement and access is limited to approved clinical research only if national authorization is given. #